Financials data is unavailable for this security.
View more
Year on year Novo Nordisk A/S grew revenues 31.26% from 176.95bn to 232.26bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.71% net income growth from 55.53bn to 83.68bn.
| Gross margin | 84.66% |
|---|---|
| Net profit margin | 35.01% |
| Operating margin | 43.75% |
| Return on assets | 27.16% |
|---|---|
| Return on equity | 88.73% |
| Return on investment | 59.83% |
More ▼
Cash flow in DKKView more
In 2023, Novo Nordisk A/S increased its cash reserves by 13.74%, or 1.74bn. The company earned 108.91bn from its operations for a Cash Flow Margin of 46.89%. In addition the company used 43.89bn on investing activities and also paid 63.16bn in financing cash flows.
| Cash flow per share | 23.23 |
|---|---|
| Price/Cash flow per share | 24.36 |
| Book value per share | 27.29 |
|---|---|
| Tangible book value per share | 14.95 |
More ▼
Balance sheet in DKKView more
| Current ratio | 0.9367 |
|---|---|
| Quick ratio | 0.7546 |
| Total debt/total equity | 0.4727 |
|---|---|
| Total debt/total capital | 0.321 |
More ▼
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 51.61% and 52.38%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 1.52% |
|---|---|
| Div growth rate (5 year) | 18.20% |
| Payout ratio (TTM) | 44.33% |
| EPS growth(5 years) | 18.50 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 27.24 |
More ▼
